12/4
08:05 am
cgtx
Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
12/3
07:30 am
cgtx
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Medium
Report
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
12/1
07:30 am
cgtx
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Medium
Report
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
11/25
01:49 pm
cgtx
Cognition Therapeutics (NASDAQ:CGTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Cognition Therapeutics (NASDAQ:CGTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/21
07:56 pm
cgtx
Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold [Seeking Alpha]
High
Report
Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold [Seeking Alpha]
11/21
10:11 am
cgtx
Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at B. Riley.
Medium
Report
Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at B. Riley.
11/20
04:37 pm
cgtx
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]
Medium
Report
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]
11/20
04:01 pm
cgtx
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
Medium
Report
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
11/19
01:17 pm
cgtx
Cognition Therapeutics (NASDAQ:CGTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Cognition Therapeutics (NASDAQ:CGTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
08:07 am
cgtx
Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
11/13
07:36 am
cgtx
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
Medium
Report
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
11/8
01:18 pm
cgtx
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at
Wall St
Low
Report
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at
Wall St
11/6
07:30 am
cgtx
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
Low
Report
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
9/27
12:39 am
cgtx
Cognition Therapeutics (NASDAQ:CGTX) was downgraded by analysts at
Wall
Medium
Report
Cognition Therapeutics (NASDAQ:CGTX) was downgraded by analysts at
Wall
9/6
12:32 am
cgtx
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at
Wall St
Medium
Report
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at
Wall St
9/6
12:32 am
cgtx
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at
Wall St
Medium
Report
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at
Wall St